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ABSTRACT 
Bartonella henselae is a Gram-negative bacterium which is the causative agent of 
cat scratch disease. Humans infection with B. henselae can result in acute or chronic 
systemic infections. The current antibiotic therapy to treat Bartonella infections is not 
very effective, presumably due to the bacterial persistence. This phenomenon gives rise 
to the importance of identifying more active drugs targeting bacterial persister cells to 
develop more effective therapies. 
Herbal products and essential oils are plant extracts containing organic chemical 
compounds. Many botanical extracts and essential oil components have been 
documented to have antimicrobial activities. Nowadays it is important to study botanical 
products with potential antimicrobial activity, especially with the great concern about 
increasing antibiotic resistance. 
In this study, we performed a high-throughput screening of two collections of herbal 
products and essential oils for active hits against stationary phase B. henselae in vitro. 
The primary screen was conducted using a SYBR Green I/propidium iodide (PI) viability 
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assay, followed by colony forming unit (CFU) assay throughout a seven-day drug 
exposure to confirm top hits. We successfully identified 3 herbal product extracts that 
had high activity against stationary phase B. henselae at 0.25% (v/v), derived from 
Cryptolepis sanguinolenta, Juglans nigra, and Polygonum cuspidatum. In addition, we 
identified 32 essential oils that had high activity against stationary phase B. henselae, 
including four essential oils extracted from Citrus plants, three from Origanum, three 
from Cinnamomum, two from Pelargonium, and two from Melaleuca, as well as 
frankincense, ylang-ylang, fir needle, mountain savory (winter), citronella, spearmint, 
elemi, vetiver, clove bud, allspice, and cedarwood essential oils. The time-kill assay 
showed 13 active hits could eradicate all stationary phase B. henselae in seven days at 
0.032% (v/v). Two active ingredients, carvacrol and cinnamaldehyde, of oregano and 
cinnamon bark essential oils, respectively, were shown to be very active such that they 
were able to eradicate all the B. henselae cells even at ≤ 0.01% (v/v). The minimum 
inhibitory concentration (MIC) determination of these active hits indicated they also had 
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good activity against log phase growing B. henselae. These findings may have 
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Bartonella henselae and its clinical significance  
Bartonella species are fastidious, Gram-negative, facultative intracellular pathogens 
[1–3] with a unique intraerythrocytic lifestyle. These bacteria can be transmitted to 
humans or other mammalian hosts by several obligately bloodsucking arthropod vectors 
including fleas, sheep keds, lice, sand flies, ticks, and potentially mites and spiders [4]. 
So far, at least 40 species or subspecies of Bartonella have been discovered [5]. 
Bartonella bacteria can infect healthy people while being considered especially 
important as opportunistic pathogens [6]. At least 13 Bartonella species are known to be 
able to infect humans, causing either acute or chronic infections which could lead to cat 
scratch disease, endocarditis, bacillary angiomatosis, trench fever, Carrion’s disease 
[3], bacteremia, central nervous system pathologies and so on [7]. This pathogenicity is 
partly due to their unique infection cycle including the lymphatic stage [8] and 
intraerythrocytic stage [4,9]. Three species of Bartonella including B. henselae, B. 
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quintana, and B. bacilliformis, are responsible for the great majority of infections in 
humans [10]. Among them, B. henselae is the most common zoonotic Bartonella 
species, with the infection distributed worldwide [11]. B. henselae is the causative 
pathogen of cat scratch disease, with symptoms of local skin lesions, malaise, 
decreased appetite, aches, headache, chills, arthritis, lymphadenopathy, fever with 
bacteremia, bacillary peliosis, and bacillary angiomatosis that could persist for several 
months [12-14]. In certain situations, cat scratch disease may lead to the development 
of serious neurologic or cardiac sequelae such as meningoencephalitis, seizures or 
endocarditis, which can have a particularly high mortality [15]. B. henselae could also 
serve as a co-infection pathogen with Lyme disease agent B. burgdorferi transmitted by 
ticks carrying multiple pathogens, leading to more severe and protracted clinical 
manifestations [16]. 
It is laborious using classical bacteriological methods to isolate and culture 
Bartonella spp. in liquid media especially from clinical samples, which requires specific 
conditions and prolonged incubation periods [17,18]. Therefore, serology and real-time 
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PCR are often used instead of culture to confirm the diagnosis for rapid Bartonella 
detection clinically [17,18]. The first-line antibiotics for treating bartonellosis include 
doxycycline, erythromycin, gentamicin, rifampicin, azithromycin, and ciprofloxacin, as 
well as some drug combinations like doxycycline plus gentamicin, doxycycline plus 
rifampin [19,20]. However, a systematic review has revealed that the current clinical 
treatment of Bartonella infections relies mostly on personal experience and expert 
opinion. The treatment lacks evidence of randomized trials and the recommended 
antibiotic treatment for cat scratch disease, infectious endocarditis, and bacillary 
angiomatosis showed no improvement in cure rate or cure time [21]. In particular, there 
is no single treatment effective for systemic B. henselae infections, and antibiotic 
therapy exhibited poor activity against typical uncomplicated cat scratch disease 
[19,20]. Therefore, bartonellosis treatment remains a significant problem and, without 
treatment, it could cause high mortality in some patients. This difficult situation could 
partly be attributed to bacterial persistence and bacterial biofilms which are resistant or 
tolerant to antibiotic treatments and can evade host immune defense [22].  
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Bacterial persistence of Bartonella henselae 
According to the Yin-Yang model theory [23], the bacterial population is highly 
heterogeneous which consists of growing (Yang) and non-growing persister (Yin) cells 
that are in varying growth and metabolic states in continuum. Persister cells may 
escape the effects of antibiotics due to epigenetic changes [24]. Therefore, Yang 
growing cells could cause active diseases at the host level, while Yin persister cells 
could remain dormant in the host during antibiotics exposure without being eradicated 
and revert to growing forms under appropriate conditions, which could lead to relapse or 
prolonged infections with symptoms [23]. The number of persister cells in a growing 
population of bacteria rises in the mid-log growth phase, with a maximum of 1% of the 
bacterial population being persisters when cultures reach the stationary phase [25]. As 
described by the Yin-Yang model, persisters can adopt varying sizes and shapes from 
regular morphology to altered morphologies as found in biofilms and L-form bacteria, 
and there would be a substantial number of persisters formed within a biofilm structure 
[26-28], which are not killed easily by current antibiotics.  
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B. henselae is capable of growing as aggregates and forms a biofilm structure on 
infected native and prosthetic heart valves. It is frequently found in the heart valve 
vegetations of patients with blood-culture-negative endocarditis [3,29]. The discrepancy 
between in vitro antibiotic susceptibility data indicated by low MICs and the failure of 
antibiotic therapy in vivo demonstrates the clinical significance of B. henselae 
persistence [30], because the in vitro tests were mainly based on growing bacteria. A 
previous study has summarized that B. henselae has a substantial capacity to tolerate 
antimicrobial agents due to bacterial persistence and biofilm formation which pose 
significant challenges for treatment [31]. Therefore, identifying drugs that target 
Bartonella persister cells in the stationary phase or biofilms could provide a promising 
strategy for developing a more effective treatment for Bartonella infections. 
 
Herbal products and essential oils as potent antimicrobials 
The use of botanical medicines was documented in the ancient cultures of 
Mesopotamia, China and India, and their safety and efficacy were demonstrated by 
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various traditional medicine systems such as Ayurveda and traditional Chinese 
medicine [32-34]. The adverse effects of botanical products were determined to be rare 
according to recent reports [35-37]. Many botanical extracts have been reported to have 
antimicrobial activities, for example, Laserpitium zernyi herb extracts were active 
against many kinds of bacteria including Pseudomonas aeruginosa, Micrococcus luteus, 
Enterococcus faecalis and Bacillus subtilis, different extracts of Ononis arvensis showed 
antimicrobial activity against Escherichia coli, P. aeruginosa, Salmonella typhimurium, 
Staphylococcus aureus and Candida albicans, and some Mediterranean herb extracts 
could inhibit microbial growth of representative oral microorganisms and biofilm 
formation of Streptococcus mutans [38-40]. Nowadays it’s worth studying herbs with 
potential antimicrobial activity for improved treatment development, especially with the 
great concern about increasing antibiotic resistance. 
The essential oil, also known as volatile oil or ethereal oil, is a concentrated 
hydrophobic liquid containing volatile chemical compounds extracted from plants. It has 
many uses in aromatherapy [41], food processing [42], and also potentially in medical 
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therapy [43]. Previous in vitro studies have found certain essential oils had antibacterial 
activity against multidrug-resistant Gram-negative clinical isolates [44]. In fact, many 
essential oil compositions including carvacrol, thymol, cinnamic acid, trans-
cinnamaldehyde, eugenol, α-pinene, and γ-terpinene were documented decades ago to 
have antimicrobial activities. Some essential oil components were shown to have a 
synergistic effect in combination with antibiotics [45]. Therefore, essential oils could 
serve as a reservoir of potentially powerful antimicrobials. 
 
An optimized SYBR Green I/PI assay for rapid viability assessment for B. 
henselae 
One conventional antibiotic susceptibility test is the Kirby–Bauer disk diffusion assay 
for growing bacteria, and the colony forming unit (CFU) assay is the most commonly 
used method to assess the killing activity of antibiotics against stationary phase 
bacteria. The residual bacterial viability after drug exposure is assessed by counting 
viable cells grown on agar plates in CFU assay. However, major disadvantages of CFU 
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assay include the laborious procedure to wash cells and make serial dilutions, the 
lengthy time for bacteria to grow on agar plates which sometimes requires several days 
or weeks, and the possibility of missing the subpopulation of viable but non-culturable 
bacteria that do not form CFUs. In order to expedite the process of antimicrobial activity 
testing, we first developed a novel approach using a SYBR Green I/Propidium iodide 
(PI) staining viability assay for high-throughput drug screens of Borrelia burgdorferi [46]. 
SYBR Green I is a high affinity dye that binds double-stranded DNA (dsDNA) and is 
commonly used to stain nucleic acids in polymerase chain reaction (PCR) and flow 
cytometric analysis [47-49], which stains all live cells green in the SYBR Green I/PI 
assay. PI is an impermeable dye that only stains dead or damaged cells with 
compromised cell membrane red [50]. Therefore, we could measure the live/dead ratio 
of a bacterial sample after drug exposure by green/red fluorescence ratio calculated 
through fluorescence microscopy or fluorescence microplate reader, which provides a 
rapid method for screening a large drug library without depending on CFU counts.  
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Our previous studies have used this SYBR Green I/PI assay for the identification of 
many herbal products and essential oils with high activity against stationary phase 
Borrelia burgdorferi [51-53] as a surrogate model of persister bacteria [54]. We have 
also successfully adapted this SYBR Green I/PI assay for the rapid viability assessment 
of B. henselae and have successfully used this assay for high-throughput drug screens 
against non-growing stationary phase B. henselae using the FDA drug library. We used 
this library to measure the linear relationship between the live/dead bacterial cell ratio 
and the green/red fluorescence ratio, and generated a regression equation and 
regression curve [55]. Here, we adapted the same SYBR Green I/PI methodology to 
perform an efficient screen using our herbal product and essential oil collections against 
stationary phase B. henselae and successfully identified a significant number of herbal 
products and essential oils that had good activity against non-growing B. henselae cells. 
We have also identified two essential oil ingredients to be highly active against 
stationary phase B. henselae. The implication of the identified active hits for improved 
treatment of persistent Bartonella infections is discussed. 
 10 
MATERIALS AND METHODS 
 
Bacterial strain, culture media and growth conditions 
The Bartonella henselae JK53 strain was obtained from BEI Resources (ATCC), 
NIAID, NIH. Based on the culture medium developed in a previous study [56], B. 
henselae JK53 was cultured in Schneider’s Drosophila medium (Life Technologies 
Limited, Paisley, UK) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, 
Co., St. Louis, MO, USA) and 5% sucrose (Fisher Scientific, New Jersey, USA). 
Cultures were incubated in sterile 15 mL or 50 mL polypropylene conical tubes 
(Corning, New York, USA) in microaerophilic incubator without shaking at 37℃, 5% 
CO2. As previously measured [55], B. henselae JK53 rapidly went into the logarithmic 
growth phase in one day and reached a growth peak after two days under such culture 
conditions. The one-day-old and five-day-old culture were considered as log phase and 
stationary phase, respectively. The Columbia anaerobic sheep blood agar (HemoStat 
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Laboratories, Dixon, CA, USA) was used to perform the colony forming unit (CFU) 
enumeration for the drug exposure assay, which was also cultured at 37 °C, 5% CO2. 
 
Preparation of antibiotics, herbal products, essential oils, and their active 
ingredients 
Antibiotics including azithromycin (AZI), daptomycin (DAP), doxycycline (DOX), 
gentamicin (GEN), methylene blue, miconazole, moxifloxacin (MXF), nitrofurantoin 
(NIT), and rifampin (RIF) were purchased from Sigma-Aldrich (USA) and dissolved in 
appropriate solvents [57] to form 10 mg/mL or 100 mM stock solutions. All the antibiotic 
stocks were filter-sterilized by 0.2 μm filters except the dimethyl sulfoxide (DMSO) 
stocks and then diluted and stored at −20 °C. 
A panel of 18 herbal products was purchased from KW Botanicals Inc. (San 
Anselmo, CA, USA) and Heron Botanicals (Kingston, WA, USA). These botanical 
products were chosen based on significant antimicrobial activity against other bacterial 
pathogens shown by previous studies [58-62], anecdotal clinical usage reported by 
 12 
patients or herbalists, favorable safety profiles and good absorption systemically. 
Botanicals were identified via macroscopic and organoleptic methods, and voucher 
specimens were on file with the respective production facilities. Additional details on 
sourcing, testing and validation of botanical and natural medicines used are 
summarized in Table S1. Most botanical extracts were provided as water extract or as 
30%, 60%, and 90% alcohol extracts, and the alcohol used was also tested separately 
as a control in the same dilutions of 30%, 60%, and 90%. Herbal products were 
dissolved in DMSO at 5% (v/v), followed by dilution at 1:5 into five-day-old stationary 
phase B. henselae JK53 cultures to achieve 1% final concentration. To make further 
dilutions for evaluating anti-Bartonella activity, the 1% herb products were further diluted 
with the same stationary phase cultures to achieve desired concentrations. 
A panel of 149 essential oils was purchased from Plant Therapy (ID, USA), Natural 
Acres (MO, USA), or Plant Guru (NJ, USA). Detailed information, as well as some GC-
MS reports of these essential oils, are available at the vendors’ websites. The main 
chemical compositions of active essential oils are summarized in Table S2 based on 
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vendors’ GC-MS reports or previous studies. Carvacrol and cinnamaldehyde were 
purchased from Sigma-Aldrich (USA). DMSO-soluble essential oils and carvacrol and 
cinnamaldehyde were dissolved in DMSO at 5% (v/v), followed by dilution at 1:10 into 
five-day-old stationary phase cultures to achieve 0.5% final concentration. To make 
further dilutions for evaluating anti-Bartonella activity, the 0.5% essential oil treatments 
were further diluted in the same stationary phase cultures to achieve desired 
concentrations. DMSO-insoluble essential oils were added directly to five-day-old 
stationary phase B. henselae cultures to form emulsion by adequate vortexing, followed 
by immediate transfer of the emulsion into the same stationary phase cultures to make 
serial dilutions to achieve desired final concentrations. 
 
Microscopy techniques  
Drug-treated or control B. henselae cell suspensions were stained with the SYBR 
Green I (100 × stock, Invitrogen) and propidium iodide (PI, 600 μM, Sigma) mixture dye 
dissolved in distilled water and then examined with BZ-X710 All-in-One fluorescence 
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microscope (KEYENCE, Inc., Osaka, Japan). The SYBR Green I/PI dye was added to 
the drug-treated sample at 1:10 dilution and mixed thoroughly, followed by incubating in 
the dark at room temperature for 15 minutes. Then the residual bacterial viability could 
be assessed by calculating the ratio of green/red fluorescence, respectively, as 
described previously [46]. The residual bacterial viability was confirmed by analyzing 
three representative images of the same bacterial cell suspension using the 
fluorescence microscopy. BZ-X Analyzer (provided by Keyence) and Image Pro-Plus 
software were used to quantitatively determine the fluorescence intensity. 
 
Screening of herbal products and essential oil collection against stationary phase 
B. henselae by SYBR Green I/PI viability assay 
For the primary high-throughput herbal products screen, each product was assayed 
in two concentrations, 1% (v/v) and 0.5% (v/v). A five-day-old stationary phase B. 
henselae JK53 culture was used for the primary screen. Firstly, 40 μL 5% herbal 
product DMSO stocks were added to 96-well plate containing 160 μL B. henselae 
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culture, respectively, to obtain the desired concentration of 1%. Then the 0.5% 
concentration was obtained by mixing 100 μL 1% treatment with 100 μL B. henselae 
culture. Antibiotics including AZI, DAP, DOX, GEN, methylene blue, miconazole, and 
RIF were used as control drugs at their Cmax. Control solvents including DMSO, 30%, 
60%, and 90% alcohol were also included. Plates were sealed and placed in 37°C 
incubator without shaking over of a period of three days. SYBR Green I/ PI viability 
assay was then used to assess the live/dead cell ratios after drug exposure as 
described [55]. Briefly, the SYBR Green I/PI dye was added to the sample followed by 
incubation in the dark for 15 minutes. The concentration of the mixed dye was 
consistent with that described above. With excitation wavelength of 485 nm and 538 nm 
and 650 nm for green and red emission, respectively, the green and red fluorescence 
intensity was determined for each sample using a microplate reader (HTS 7000 plus 
Bioassay Reader, PerkinElmer Inc., USA). Then the residual bacterial viability was 
calculated according to the regression equation of the relationship between residual 
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viability percentage and green/red fluorescence ratio obtained by least-square fitting 
analysis as previously described [55]. All tests were run in triplicate. 
For the primary high-throughput essential oil screen, each essential oil was assayed 
in two concentrations, 0.5% (v/v) and 0.25% (v/v). Firstly, 20 μL 5% essential oil DMSO 
stocks or emulsion were added to the 96-well plate containing 180 μL of the five-day-old 
stationary phase B. henselae JK53 culture to obtain the desired concentration of 0.5%. 
Then, the 0.25% treatment concentration was obtained by mixing 100 μL 0.5% 
treatment with 100 μL five-day-old B. henselae JK53 culture. Antibiotics including AZI, 
DAP, DOX, GEN, methylene blue, miconazole, MXF, NIT, and RIF were used as control 
drugs at 20 μM. Plates were sealed and placed in a 37 °C incubator without shaking 
over a period of three days. SYBR Green I/ PI viability assay was used to assess the 





Drug exposure assay of active hits by CFU counting on agar plates 
Based on primary screening results, active hits were further confirmed by the drug 
exposure CFU assay. The five-day-old stationary phase B. henselae culture was used 
for drug exposure experiments, which was treated with 0.25% (v/v) active herbal 
products or 0.032% (v/v) active essential oils respectively. Then two highly potent active 
ingredients, carvacrol, and cinnamaldehyde, of active essential oils oregano and 
cinnamon bark, respectively, were also tested by drug exposure assay at a very low 
concentration of 0.01% (v/v) and 0.005% (v/v). Control antibiotics including AZI, DAP, 
DOX, GEN, methylene blue, miconazole, and RIF were used at their Cmax. Solvents 
including DMSO, 30%, 60%, and 90% alcohol were also included as controls for herbal 
products assay. The drug exposure assay was carried out in 15 mL polypropylene 
conical tubes over the course of seven days at 37 °C, 5% CO2 without shaking. At each 
time point we measured, a portion of bacteria cells was collected by centrifugation and 
rinsed twice with fresh Schneider's medium followed by resuspension in fresh 
Schneider's medium. Then the cell suspension was serially diluted and each dilution 
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was plated on Columbia blood agar plates for viable bacterial CFU counts. The plates 
were incubated at 37 °C, 5% CO2 until visible colonies appeared and the CFU/mL was 
calculated accordingly. All tests were run in triplicate. 
 
Minimum inhibitory concentration (MIC) determination of active hits 
The standard microdilution method was used to measure the minimum inhibitory 
concentration (MIC) of each active herbal product or essential oil needed to inhibit the 
visible growth of B. henselae after a five-day incubation period as described [55]. The 
diluted one-day-old logarithmic phase B. henselae culture was used for MIC 
determination. 1×106 bacterial cells were inoculated into the well of the 96-well plate 
containing 160 μL fresh modified Schneider’s medium per well. Then 40 μL 5% herbal 
product or essential oil stocks were added into each well respectively to achieve 1% 
final concentration. Other lower concentrations were obtained by mixing 1% treatment 
with diluted one-day-old log phase B. henselae culture. Plates were sealed and 
incubated at 37 °C without shaking for five days. Then the bacterial cell proliferation was 
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assessed using the SYBR Green I/PI assay as described above and the bacterial 
counting chamber after the incubation. The MIC is the lowest concentration of the drug 
that prevented the visible growth of B. henselae. All tests were run in triplicate. 
 
Statistical Analysis 
The statistical analysis was performed using two-tailed Student’s t-test and two-way 
ANOVA where appropriate. Mean differences were considered statistically significant if 
p was <0.05. All experiments were performed in triplicate. Analyses were performed 










I. Evaluation of herbal product collection for activity against B. henselae 
 
Screening the herbal product collection to identify active hits against non-
growing stationary phase B. henselae  
Previously, we have developed an SYBR Green I/PI viability assay for the rapid 
viability assessment of B. henselae and have successfully used this assay for high-
throughput drug screens against non-growing stationary phase B. henselae using the 
FDA-approved drug library [55]. Although the standard CFU assay can be used to 
evaluate the activity of different drugs against stationary phase B. henselae, it would be 
much more tedious. Thus, we screened the FDA drug library by using the SYBR Green 
I/PI assay which is a more rapid method with the potential to be used for more high-
throughput drug screens [55]. Here we adapted this SYBR Green I/PI viability assay for 
herbal product screens against B. henselae. As described in the previous study [55], a 
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five-day-old stationary phase B. henselae culture was used to identify active herbal 
products against stationary phase B. henselae. All herbal products were applied at two 
concentrations, 1% (v/v) and 0.5% (v/v), respectively, in the primary screens, along with 
their solvents tested separately for comparison. Meanwhile, the currently known 
effective antibiotics used to treat bartonellosis such as AZI, DOX, GEN, and RIF were 
included as control drugs for comparison (Table 1). In addition, we included previously 
identified FDA-approved drugs that were effective against stationary phase B. henselae 
such as DAP, methylene blue, and miconazole [55] as controls (Table 1). All these 
antibiotics were used at their Cmax. In the primary screens, after the three-day drug 
exposure, 7 of the 18 herbal products in the collection were found to have good activity 
against stationary phase B. henselae both at the concentration of 1% (v/v) and 0.5% 
(v/v) as shown by plate reader results, and thus were selected as top hits. The top 7 
active hits included Juglans nigra fruit extract, Juglans nigra 30%, 60%, and 90% 
alcohol extract, two different extracts from Polygonum cuspidatum, Cryptolepis 
sanguinolenta 30%, 60%, and 90% alcohol extract, Scutellaria baicalensis, and 
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Scutellaria barbata. These top hits were chosen based on their lower percentage of 
viable cells remaining after herbal product treatment than that for the current antibiotics 
used to treat Bartonella infections, including AZI, DOX, GEN, and RIF. According to our 
previous experience, some compounds in the herbal products can cause interference 
with the SYBR Green I/PI assay because of color and autofluorescence. Thus, we 
selected these 7 top hits for further validation by microscopic counting to confirm the 
SYBR Green I/PI plate reader results. The currently used antibiotics for bartonellosis 
treatment and the identified FDA-approved drugs effective against B. henselae were 
also included as controls for comparison. AZI and DOX as control drugs showed poor 
activity against stationary phase B. henselae (residual viability above 60%) (Table 1), as 
expected. Antibiotics reported to have a clinical improvement for Bartonella infection 
including GEN and RIF [30,63] showed relatively better activity (residual viability below 
50%) against stationary phase B. henselae than AZI and DOX. FDA-approved drugs 
that we identified as effective against stationary phase B. henselae (DAP, methylene 
blue, and miconazole) had better activity (residual viability below 40%) than most of the 
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four antibiotics mentioned above. The difference of residual viabilities of stationary 
phase B. henselae after treatment by control solvents and without drug treatment were 
not statistically significant. 
 









Residual Viability (%) 
after 1% HP or Antibiotic 
Treatment 
Residual Viability (%) 







control  70% 75%   
DMSO control  60% 70%   
30% alcohol  70% 78%   
60% alcohol  80% 82%   
90% alcohol  65% 63%   
AZI  70% 65%   
DOX  66% 60%   
GEN  44% 50%   
RIF  31% 45%   
DAP  6% 10%   
Methylene Blue  29% 35%   
Miconazole  40% 50%   
Hu tao ren Juglans nigra fruit (husk/hull) 0%
4 0% 9% 59% 
Black walnut 
60% AE5 Juglans nigra 0%
4 0% 4% 32% 
Black walnut 
90% AE5 Juglans nigra 0%
4 7% 6% 30% 
Black walnut 




cuspidatum 6% 0% 8% 21% 




sanguinolenta 8% 10% 14% 42% 
Huang qin Scutellaria baicalensis  8% 12% 11% 25% 
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sanguinolenta 11% 25% 14% 47% 
1 A five-day-old stationary phase B. henselae culture was treated with herbal products (1% or 0.5%) (v/v) 
or control drugs for three days. Drug concentrations used in this experiment were based on their Cmax and 
were as follows: 0.2 μg/mL AZI, 2.4 μg/mL DOX, 10 μg/mL GEN, 7.8 μg/mL RIF, 60 μg/mL DAP, 2.9 μg/mL 
methylene blue, and 6.3 μg/mL miconazole. 2 Residual viability was calculated according to the regression 
equation and the ratio of Green/Red fluorescence obtained by SYBR Green I/PI assay. 3 Residual viability 
was assayed by fluorescence microscope counting. 4 Values of SYBR Green I/PI calculated by the plate 
reader were lower than 100% dead cells. 5Abbreviation: AE: alcohol extract. 
 
Among the 7 top hits that had better activity (residual viability between 0% and 16%) 
against stationary phase B. henselae than most control antibiotics, the most active 
herbal products were extracts from Juglans nigra and Polygonum cuspidatum, including 
hu tao ren, black walnut alcohol extracts of different concentrations, Japanese 
knotweed, and hu zhang. However, the fluorescence microscope observation of hu tao 
ren, black walnut 30% AE, and hu zhang at 0.5% treatment exhibited significantly higher 
percentage of green (live) cells compared with the plate reader results (Figure 1)(Table 
1), which were also higher than that of most control antibiotics, indicating the relatively 
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poor accuracy of the plate reader results and poor activity of these herbal products at 
these particular herbal concentrations. Therefore, they were excluded from active hits 
for subsequent MIC testing and drug exposure assay (see below). Alcohol extracts from 
Cryptolepis sanguinolenta of different concentrations also exhibited strong activity 
against stationary phase B. henselae as shown by red (dead) cells in fluorescence 
microscope observation (Figure 1), which is consistent with the plate reader results. 
Extracts from two plants of Scutellaria genus, including Scutellaria baicalensis (huang 
qin) and Scutellaria barbata (ban zhi lian), also showed remarkable effects with low 
percentages of residual viable bacterial cells remaining (Figure 1). Control drugs 
including AZI and DOX exhibited poor activity against stationary phase B. henselae as 
shown by many green (live) cells in fluorescence microscope observation, and other 
antibiotics including GEN, RIF, DAP, methylene blue, and miconazole showed better 
activity but not as good as most of the 7 top hits (Figure 1). 
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Figure 1. Effect of 7 top hits of herbal products against stationary phase B. henselae in comparison 
with control drugs. A five-day-old stationary phase B. henselae culture was treated with 1% (v/v) or 0.5% 
Drug free DMSO 30% alcohol 60% alcohol
90% alcohol AZI DOX GEN
RIF Methylene blue MiconazoleDAP
Hu tao ren Black walnut 60% AE Black walnut 90% AE Black walnut 30% AE
Japanese knotweed Hu zhang Cryptolepis 30% AE Huang qin
Hu tao ren Black walnut 60% AE Black walnut 90% AE Black walnut 30% AE
Japanese knotweed Hu zhang Cryptolepis 30% AE Huang qin
Ban zhi lian Cryptolepis 60% AE Cryptolepis 90% AE
Ban zhi lian Cryptolepis 60% AE Cryptolepis 90% AE
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(v/v) herbal products or control antibiotics for three days followed by SYBR Green I/PI viability assay and 
fluorescence microscopy (400 × magnification). Drug concentrations used in this experiment were based 
on their Cmax and were as follows: 0.2 μg/mL AZI, 2.4 μg/mL DOX, 10 μg/mL GEN, 7.8 μg/mL RIF, 60 
μg/mL DAP, 2.9 μg/mL methylene blue, and 6.3 μg/mL miconazole. Green cells represent live cells and red 
cells represent dead cells. 
 
MIC determination of active hits in the herbal product collection 
The activity of antibiotics against non-growing bacteria is not always correlated with 
that against growing bacteria [55]. Thus, it was also necessary to determine the MICs of 
these active herbal products against log phase growing B. henselae. The MIC 
determination of herbal products for B. henselae was conducted by the standard 
microdilution method, as described in our previous study [55]. As shown in Table 2, 
black walnut 60% alcohol extract was the most active herbal product among the top 7 
hits, capable of inhibiting visible B. henselae proliferation at the concentration of 
0.125%-0.25% (v/v). Other herbal products including black walnut 90% alcohol extracts, 
Japanese knotweed, cryptolepis 30%, 60%, and 90% alcohol extracts, huang qin, and 
ban zhi lian had similar activity against growing B. henselae that they inhibited log 
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phase B. henselae proliferation at the concentration of 0.25%-0.5% (v/v). These results 
indicated that these top hits of herbal products were not only active against non-growing 
stationary phase B. henselae, but also effective against log phase growing B. henselae. 
 
Table 2. Minimum inhibitory concentrations (MICs) of top active herbal products against 
B. henselae 
Natural Products Plant or Ingredients of Herbal 
Products 
MIC (v/v) 
Black walnut 60% AE Juglans nigra 0.125%-0.25% 
Black walnut 90% AE Juglans nigra 0.25%-0.5% 
Japanese knotweed Polygonum cuspidatum 0.25%-0.5% 
Cryptolepis 30% AE Cryptolepis sanguinolenta 0.25%-0.5% 
Cryptolepis 60% AE Cryptolepis sanguinolenta 0.25%-0.5% 
Cryptolepis 90% AE Cryptolepis sanguinolenta 0.25%-0.5% 
Huang qin Scutellaria baicalensis  0.25%-0.5% 
Ban zhi lian Scutellaria barbata 0.25%-0.5% 
 
Time-kill curves of active hits from the herbal product collection 
To further demonstrate the efficacy of the active herbal products identified from the 
primary screens in eradicating non-growing B. henselae persistent cells, we performed 
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a time-kill drug exposure assay against a five-day-old B. henselae stationary phase 
culture at a low concentration of 0.25% (v/v), along with their corresponding solvent 
controls. Meanwhile, clinically used antibiotics to treat Bartonella infections including 
AZI, DOX, GEN, and RIF were used at their Cmax as controls. Compared to the drug 
free control, as shown in Figure 2 and Table 3, some clinically used antibiotics such as 
azithromycin and doxycycline showed poor activity in killing stationary phase B. 
henselae partly due to their low Cmax. Other antibiotics such as GEN and RIF exhibited 
better activity which could eradicate all B. henselae cells by day 7 and day 5. The 
difference of residual viabilities of stationary phase B. henselae after treatment by 
control solvents and without drug treatment were not statistically significant. All three 
cryptolepis alcohol extracts of different concentrations were able to eradicate all B. 
henselae cells in the seven-day drug exposure, where cryptolepis 60% alcohol extract 
was the most active herbal product that killed B. henselae with no detectable CFU after 
five-day exposure. Black walnut in 60% and 90% alcohol extracts both exhibited good 
activity that eradicated all B. henselae cells without viable cells being recovered after 
 30 
the seven-day drug exposure. Japanese knotweed was also effective to kill all B. 
henselae cells by day 7. However, ban zhi lian and huang qin herbal products showed 
poor activity at the concentration of 0.25% (v/v) during this seven-day drug exposure, 
with considerable numbers of residual viable cells remaining after treatment. 
 
 
Figure 2. Time-kill curves of active herbal products treatment against stationary phase B. henselae 
in comparison with control drugs. The herbal products or control antibiotics were added to the five-day 
old stationary phase culture respectively at time point 0, and at different times of drug exposure (day 1, day 
3, day 5, and day 7), portions of bacteria were removed and washed and plated on Columbia blood agar 
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plates for CFU counts. The herbal product concentration used in this experiment was 0.25% (v/v). Drug 
concentrations used in this experiment were based on their Cmax and were as follows: 0.2 μg/mL AZI, 2.4 
μg/mL DOX, 10 μg/mL GEN, and 7.8 μg/mL RIF. 
 
Table 3. Drug exposure assay of top active herbal products against B. henselae 




CFU/mL after Drug Exposure 
1 Day 3 Day 5 Day 7 Day 
Drug free 
control 1.45 ± 0.26 × 10
7 9.17 ± 1.44 × 106 1.67 ± 0.29 × 106 1.33 ± 0.29 × 104 
DMSO 2.07 ± 0.12 × 107 9.33 ± 0.58 × 106 1.50 ± 0.50 × 106 1.50 ± 0.50 × 104 
30% alcohol 4,17 ± 1.04 × 107 9.50 ± 1.32 × 106 1.33 ± 0.58 × 106 1.83 ± 0.76 × 104 
60% alcohol 3.33 ± 0.29 × 107 1.02 ± 0.13 × 107 2.50 ± 1.00 × 106 2.17 ± 0.29 × 104 
90% alcohol 3.17 ± 0.29 × 107 9.00 ± 1.50 × 106 1.17 ± 0.29 × 106 4.33 ± 1.15 × 104 
AZI 1.87 ± 0.32 × 107 7.00 ± 1.00 × 106 8.83 ± 1.44 × 105 2.17 ± 0.29 × 104 
DOX 2.50 ± 1.00 × 107 6.17 ± 1.76 × 106 9.67 ± 2.47 × 105 1.83 ± 1.15 × 104 
GEN 5.00 ± 0.00 × 104 1.00 ± 0.00 × 103 8.50 ± 0.87 × 102 0 
RIF 5.83 ± 1.76 × 106 5.83 ± 2.57 × 104 0 0 
Black walnut  
60% AE 3.67 ± 0.76 × 10
6 6.67 ± 2.89 × 104 1.02 ± 0.21 × 105 0 
Black walnut  
90% AE 3.83 ± 3.69 × 10
6 2.67 ± 0.58 × 106 4.83 ± 1.04 × 102 0 
Cryptolepis 
30% AE 6.00 ± 0.87 × 10
6 2.83 ± 0.76 × 106 6.33 ± 1.26 × 104 0 
Cryptolepis 
60% AE 5.33 ± 2.25 × 10
4 2.67 ± 1.04 × 105 0 0 
Cryptolepis 
90% AE 7.83 ± 2.75 × 10
6 9.50 ± 3.97 × 105 2.17 ± 1.04 × 102 0 
Japanese 
knotweed 7.17 ± 1.61 × 10
6 2.33 ± 0.29 × 106 5.50 ± 3.12 × 102 0 
Ban zhi lian 1.03 ± 0.20 × 107 3.17 ± 1.04 × 106 3.17 ± 0.58 × 105 3.17 ± 0.58 × 103 
Huang qin 9.00 ± 0.50 × 106 2.83 ± 0.76 × 106 6.50 ± 2.78 × 105 7.83 ± 0.29 × 103 
1 A five-day-old stationary phase B. henselae culture was treated with herbal products or control drugs. The 
beginning CFU for the five-day-old stationary phase B. henselae culture was about 2 × 107 CFU/mL. At 
different time points of drug exposure (day 1, day 3, day 5, and day 7), portions of bacteria were removed, 
washed, and plated on Columbia blood agar for CFU counts. 2 The herbal product concentration used in 
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this experiment was 0.25% (v/v). Drug concentrations used in this experiment were based on their Cmax 
and were as follows: 0.2 μg/mL AZI, 2.4 μg/mL DOX, 10 μg/mL GEN, and 7.8 μg/mL RIF. 
 
 
II. Evaluation of essential oil collection for activity against B. henselae 
This part of the study was recently published: X. Ma, W. Shi, Y. Zhang. Essential Oils 
with High Activity against Stationary Phase Bartonella henselae. Antibiotics. 2019, 8(4), 
246. https://doi.org/10.3390/antibiotics8040246 
 
Screening the essential oil collection to identify drugs active against non-growing 
stationary phase B. henselae  
Similarly, we adapted the SYBR Green I/PI viability assay developed previously [55] 
to identify essential oils with good activity against stationary phase B. henselae. As 
described above, we tested a panel of essential oils and their corresponding controls 
against a five-day-old stationary phase B. henselae culture in 96-well plates incubated 
for three days. For primary screens, all 149 essential oils were applied at two 
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concentrations, 0.5% (v/v) and 0.25% (v/v), respectively. Meanwhile, the currently used 
antibiotics for bartonellosis treatment such as AZI, DOX, GEN, MXF, and RIF were 
included as control drugs for comparison, as well as the previously identified FDA-
approved drugs effective against stationary phase B. henselae including DAP, 
methylene blue, miconazole, and NIT [55] (Table 3). All these antibiotics were used at 
20 μM. In the primary screens, after the three-day drug exposure, 32 of 149 essential 
oils in the collection were found to have good activity against stationary phase B. 
henselae both at the concentration of 0.5% (v/v) and 0.25% (v/v), and thus were 
selected as top hits. The top 32 active hits were chosen based on their lower 
percentage of viable cells remaining after essential oil treatment than that for the current 
antibiotics used to treat Bartonella infections, including AZI, DOX, GEN, MXF, and RIF. 
Similar to herbal products, some compounds in the essential oils can cause interference 
with the SYBR Green I/PI assay because of color and autofluorescence. Thus, we 
selected these 32 top hits for further validation by microscopic counting to confirm the 
SYBR Green I/PI plate reader results. The currently used antibiotics for bartonellosis 
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treatment and the identified FDA-approved drugs effective against B. henselae were 
also included as controls for comparison at 20 μM. DOX as a control drug showed mild 
activity against stationary phase B. henselae (residual viability above 26%) (Table 3). 
Other clinically used antibiotics to treat Bartonella infection including MXF, GEN, AZI, 
and RIF [30,63] showed relatively better activity (residual viability between 9% and 
25%) against stationary phase B. henselae than DOX. FDA-approved drugs that we 
identified as effective against stationary phase B. henselae (DAP, methylene blue, 
miconazole, and NIT) had better activity (residual viability between 8% and 19%) than 
most of the five antibiotics mentioned above. 
 





Plant or Ingredients 
of Essential Oils 
Residual Viability (%) 
after 0.5% EO or 20 μM 
Antibiotic Treatment 
Residual Viability (%) 







control  74% 74%   
DOX  26% 57%   
GEN  9% 35%   
MXF  22% 40%   
AZI  23% 67%   
RIF  25% 44%   
DAP  8% 18%   
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Methylene 
Blue  16% 27%   
NIT  18% 50%   
Miconazole  19% 44%   
Frankincens
e  Boswellia serrata 5% 11% 6% 10% 
Ylang ylang Cananga odorata 5% 9% 8% 10% 
Tangerine Citrus reticulata 6% 6% 5% 12% 
Bergamot Citrus bergamia 6% 18% 10% 15% 
Marjoram 
(sweet) Origanum majorana 6% 13% 5% 15% 
Cajeput Melaleuca cajeputi 7% 21% 9% 21% 
Lemon Citrus limonum 7% 10% 4% 11% 




graveolens 8% 20% 11% 22% 
Tea tree Melaleuca alternifolia 8% 12% 5% 25% 
Fir needle Abies siberica 8% 25% 10% 26% 
Stress relief  
synergy blend of 
essential oils of 
bergamot, patchouli, 
sweet orange, ylang 
ylang, pink grapefruit, 
gurjum 




Satureja montana 8% 25% 21% 32% 
Bandit  
synergy blend of 
essential oils of clove, 
cinnamon, lemon, 
rosemary, eucalyptus 




zeylanicum 8% 35% 10% 25% 
Citronella Cymbopogon winterianus 8% 15% 12% 23% 
Health shield  
blend of cinnamon, 
clove, eucalyptus, 
lemon and rosemary 
oils  
9% 18% 17% 20% 
Spearmint Mentha spicata 9% 9% 4% 20% 
Ho wood Cinnamomum camphora 9% 20% 11% 29% 
Tic Tox aux 
huiles 
essentielles 
blend of essential oils 




cinnamon and niaouli 
11% 21% 14% 14% 
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Citrus blast 
synergy blend of 
Citrus sinesis, Citrus 
limonum, Citrus 






11% 13% 11% 30% 
Elemi Canarium luzonicum 12% 25% 14% 32% 
Vetiver Vetiveria zizanoides 12% 26% 8% 18% 
Grapefruit  Citrus paradisi 12% 35% 11% 36% 
Clove bud 1 Eugenia caryophyllata 13% 36% 9% 23% 
Deep forest 
synergy blend of 
Abies sibirica ledeb, 




13% 20% 12% 50% 
Geranium Pelargonium asperum 14% 23% 15% 20% 




hirtum 15% 52% 19% 55% 
Allspice Pimenta officinalis 16% 35% 6% 30% 




zeylanicum 18% 40% 13% 45% 
1 A five-day-old stationary phase B. henselae culture was treated with essential oils (0.5% or 0.25%) (v/v) 
or control drugs (20μM) for three days. 2 Residual viability was calculated according to the regression 
equation and the ratio of Green/Red fluorescence obtained by SYBR Green I/PI assay. 3 Residual viability 
was assayed by fluorescence microscope counting.  
 
The microscopic counting aligned well with the plate reader results. Among the 32 
top hits that had better activity (residual viability between 5% and 21%) against 
stationary phase B. henselae than most control antibiotics, the most active essential oils 
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were ylang-ylang, lemon, stress relief, health shield, Tic Tox aux huiles essentielles, 
geranium essential oil, clove bud, and cedarwood because of their remarkable activity 
at 0.25%, as shown by red (dead) cells in fluorescence microscope observation (Figure 
3). Essential oils made from oregano (“oregano” and “oil of oregano”) and cinnamon 
(“cinnamon leaf” and “cinnamon bark”) were all shown to be highly active against 
stationary phase B. henselae, which have already been identified effective against 
stationary phase B. burgdorferi in our previous study [51]. Some essential oils extracted 
from plants of the same genus as oregano or cinnamon also exhibited good activity 
against stationary phase B. henselae. For example, ho wood, which was also extracted 
from Cinnamomum spp. as cinnamon essential oils were shown to be active. Marjoram 
(sweet), which was extracted from Origanum spp. as oregano essential oils were also 
active. In addition, essential oils extracted from Citrus spp. including tangerine, 
bergamot, lemon, and grapefruit all exhibited strong activity against stationary phase B. 
henselae, and the same for essential oils extracted from Pelargonium spp. (geranium 
bourbon and geranium essential oil) and Melaleuca spp. (cajeput and tea tree essential 
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oil). Many blended essential oils including “stress relief”, “bandit”, “health shield”, “Tic 
Tox”, “citrus blast”, and “deep forest” exhibited strong activity against stationary phase 
B. henselae because some of their components, such as clove, ylang ylang, lemon, 
bergamot, grapefruit, cinnamon, oregano, and fir needle were shown to be active as 
single essential oils. Control drugs including DOX and AZI exhibited poor activity 
against stationary phase B. henselae as shown by green (live) cells using fluorescence 
microscope observation. Other antibiotics including GEN, MXF, RIF, DAP, methylene 
blue, NIT, and miconazole showed better activity, while not as good as most of the 32 
top hits (Figure 3). 
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Figure 3. Effect of 32 top hits of essential oils against stationary phase B. henselae in comparison 
with control drugs. A five-day-old stationary phase B. henselae culture was treated with 0.25% (v/v) 
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essential oils or control antibiotics (20μM) for three days followed by SYBR Green I/PI viability assay and 
fluorescence microscopy (400 × magnification). Green cells represent live cells and red cells represent 
dead cells. 
 
MIC determination of active hits in the essential oil collection 
The essential oils listed above were active against the non-growing stationary phase 
B. henselae (Table 3 and Figure 3), and it was necessary to determine the MICs of 
these active drugs against log-phase growing B. henselae. The MICs of essential oils 
for B. henselae were determined by the standard microdilution method, as described in 
our previous study [55]. As shown in Table 4, cinnamon bark was the most active 
essential oil among these 32 hits, capable of inhibiting visible B. henselae proliferation 
at the lowest concentration of the essential oils tested (0.008%). The health shield, a 
blend of many active compounds against non-growing B. henselae was also highly 
active against growing B. henselae, which could inhibit B. henselae proliferation at a 
concentration of 0.008–0.016%. And the growth of B. henselae was efficiently 
suppressed by bandit, elemi, mountain savory (winter), cedarwood and two oregano 
essential oils at 0.016–0.032%, and by ylang-ylang, citronella, clove bud, geranium 
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bourbon, allspice, vetiver, cinnamon leaf and geranium essential oil at 0.032–0.063%. 
Other single essential oils including bergamot, cajeput, marjoram (sweet), fir needle, 
grapefruit as well as blends of essential oils including stress relief, citrus blast, and deep 
forest were also active with MIC values of 0.063–0.125%. B. henselae growing cells 
were also susceptible to spearmint, tangerine, tea tree, lemon, ho wood, frankincense, 
and Tic Tox aux huiles essentielles at a concentration of 0.125–0.25%, although at 
relatively higher concentrations than other oils tested. 
 
Table 5. Minimum inhibitory concentrations (MICs) of top active essential oils against B. 
henselae 
Essential Oils Plant or Ingredients of Essential Oils MIC (v/v) 
Cinnamon bark Cinnamomum zeylanicum <0.008% 
Health shield blend of cinnamon, clove, eucalyptus, lemon and rosemary oils 0.008–0.016% 
Bandit  synergy blend of essential oils of clove, cinnamon, lemon, rosemary, eucalyptus 0.016–0.032% 
Oregano Origanum vulgare hirtum 0.016–0.032% 
Elemi Canarium luzonicum 0.016–0.032% 
Oil of oregano Origanum vulgare hirtum 0.016–0.032% 
Mountain 
savory (winter) Satureja montana 0.016–0.032% 
Cedarwood Cedrus deodora 0.016–0.032% 
Ylang ylang Cananga odorata 0.032–0.063% 
Citronella Cymbopogon winterianus 0.032–0.063% 
Clove bud 1 Eugenia caryophyllata 0.032–0.063% 
Clove bud 2 Syzygium aromaticum L 0.032–0.063% 
Geranium 
bourbon Pelargonium graveolens 0.032–0.063% 
Allspice Pimenta officinalis 0.032–0.063% 
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Vetiver Vetiveria zizanoides 0.032–0.063% 
Cinnamon leaf Cinnamomum zeylanicum 0.032–0.063% 
Geranium Pelargonium asperum 0.032–0.063% 
Stress relief  synergy blend of essential oils of bergamot, patchouli, sweet orange, ylang ylang, pink grapefruit, gurjum 0.063–0.125% 
Bergamot Citrus bergamia 0.063–0.125% 
Cajeput Melaleuca cajeputi 0.063–0.125% 
Marjoram 
(sweet) Origanum majorana 0.063–0.125% 
Citrus blast synergy blend of essential oils of bergamot, patchouli, sweet orange, ylang ylang, pink grapefruit, gurjum 0.063–0.125% 
Deep forest synergy blend of Abies sibirica ledeb, Abies alba, Pinus sylvestris, Cupressus sempervirens, Cedrus deodora 0.063–0.125% 
Fir needle Abies siberica 0.063–0.125% 
Grapefruit  Citrus paradisi 0.063–0.125% 
Spearmint Mentha spicata 0.125–0.25% 
Tangerine Citrus reticulata 0.125–0.25% 
Tea tree Melaleuca alternifolia 0.125–0.25% 
Lemon Citrus limonum 0.125–0.25% 
Ho wood Cinnamomum camphora 0.125–0.25% 
Frankincense Boswellia serrata 0.125–0.25% 
Tic Tox aux 
huiles 
essentielles 
 blend of essential oils of savory, sage officinale, wild 





Time-kill curves of active hits in the essential oil collection 
Having obtained 32 top hits by primary screens, we performed a time-kill drug 
exposure assay against a five-day-old stationary phase B. henselae culture at a lower 
concentration of these active essential oils. Here we just selected single essential oil 
samples for a drug exposure assay in order to better evaluate and compare the activity 
of antimicrobial components among different essential oils. All selected 25 essential oils 
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were applied at 0.032% (v/v), respectively. Clinically used antibiotics and the previously 
identified effective FDA-approved drugs against B. henselae were used at their Cmax 
as controls. As shown in Table 5 and Figure 4b & 4c, oregano, cinnamon bark, and 
mountain savory (winter) were the most active essential oils that rapidly killed B. 
henselae with no detectable CFU after one-day exposure. Other active hits, including 
clove bud 2, allspice, geranium, and cinnamon leaf could eradicate B. henselae cells 
without viable cells being recovered after a three-day drug exposure. Geranium bourbon 
and clove bud 1 also showed excellent activity which could kill all bacteria by day 5, 
followed by elemi, vetiver, citronella and ylang ylang that eradicated all B. henselae 
cells by day 7. 
As shown in Table 5, grapefruit, tangerine, bergamot, fir needle, frankincense and 
ho wood were also quite active, reducing 5 log10 CFU/mL after a seven-day exposure. 
Lemon, as well as marjoram (sweet) also had the capability of killing stationary phase B. 
henselae and reduced the bacterial count by approximately 3 log10 CFU/mL in seven 
days. However, cajeput, tea tree, cedarwood, and spearmint showed poor activity. 
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Compared with the drug-free control, as shown in Figure 4a, some clinically used 
antibiotics for Bartonella treatment, such as AZI and DOX, had poor activity in killing B. 
henselae, achieving approximately 1 log10 CFU/mL decrease after the seven-day drug 
exposure. GEN and RIF showed better activity than AZI and DOX when used at their 
Cmax, which could eradicate all B. henselae cells respectively by day 3 and day 7. 
Other FDA-approved drugs effective against B. henselae including DAP and methylene 
blue had good activity that led to the eradication of B. henselae cells after a one-day or 
five-day exposure, respectively, while miconazole did not kill all B. henselae cells by day 
7 when used at Cmax. 
 
 
Figure 4. Time-kill curves of active essential oil treatment against stationary phase B. henselae in 
comparison with control drugs. (a) Time-kill curves for control antibiotic treatment. (b–c) Time-kill curves 
for essential oil treatment. Drug-free control, DAP, GEN, methylene blue, and RIF treatment were the same 
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among a, b, and c. The essential oils or control antibiotics were added to a five-day-old stationary phase 
culture respectively at time point 0, and at different times of drug exposure (day 1, day 3, day 5, and day 
7), portions of bacteria were removed and washed and plated on Columbia blood agar plates for CFU 
counts. The essential oil concentration used in this experiment was 0.032% (v/v). Drug concentrations used 
in this experiment were based on their Cmax and were as follows: 0.2 μg/mL AZI, 2.4 μg/mL DOX, 10 
μg/mL GEN, 7.8 μg/mL RIF, 60 μg/mL DAP, 2.9 μg/mL methylene blue, and 6.3 μg/mL miconazole. 
 
Table 6. Drug exposure assay of top active essential oils against B. henselae stationary 




CFU/mL after Drug Exposure 
1 Day 3 Day 5 Day 7 Day 
Drug free 
control 1.50 ± 0.53 × 10
7 8.83 ± 0.29 × 106 1.88 ± 0.40 × 106 2.67 ± 0.29 × 106 
DOX 4.17 ± 1.44 × 107 5.07 ± 0.38 × 106 2.30 ± 0.10 × 106 8.33 ± 2.89 × 105 
AZI 4.50 ± 2.00 × 107 9.17 ± 0.29 × 106 3.80 ± 0.72 × 106 2.83 ± 1.04 × 105 
GEN 9.83 ± 2.93 × 104 0 0 0 
RIF 1.27 ± 0.15 × 107 8.33 ± 0.76 × 104 5.17 ± 0.29 × 103 0 
DAP 0 0 0 0 
Methylene blue 1.35 ± 0.13 × 106 3.17 ± 0.58 × 103 0 0 
Miconazole 5.83 ± 1.53 × 106 1.57 ± 0.28 × 106 8.50 ± 1.32 × 105 1.30 ± 0.10 × 104 
Oregano 0 0 0 0 
Cinnamon bark 0 0 0 0 
Mountain 
savory (winter) 0 0 0 0 
Clove bud 2 6.50 ± 3.46 × 102 0 0 0 
Allspice 2.27 ± 0.33 × 103 0 0 0 
Geranium 4.83 ± 0.76 × 103 0 0 0 
Cinnamon leaf 1.33 ± 0.35 × 104 0 0 0 
Geranium 
bourbon 5.50 ± 2.65 × 10
3 5.00 ± 5.00 × 10 0 0 
Clove bud 1 5.00 ± 0.00 × 104 8.33 ± 5.77 × 10 0 0 
Elemi 1.38 ± 0.42 × 103 5.00 ± 5.00 × 10 2.17 ± 1.04 × 102 0 
Vetiver 2.00 ± 0.50 × 105 1.18 ± 0.19 × 104 5.17 ± 2.47 × 102 0 
Citronella 1.13 ± 0.12 × 104 7.33 ± 2.84 × 103 4.50 ± 0.87 × 103 0 
Ylang ylang 2.00 ± 0.87 × 105 2.38 ± 0.19 × 105 7.83 ± 3.01 × 104 0 
Grapefruit 1.02 ± 0.19 × 104 3.17 ± 1.89 × 104 5.33 ± 1.26 × 103 6.67 ± 5.77 × 10 
Tangerine 3.17 ± 0.29 × 104 2.08 ± 0.58 × 104 4.50 ± 2.29 × 103 6.67 ± 5.77 × 10 
Bergamot 8.17 ± 2.25 × 103 2.62 ± 0.35 × 104 6.83 ± 0.76 × 103 1.67 ± 0.58 × 102 
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Fir needle 4.17 ± 1.61 × 103 2.32 ± 0.41 × 104 1.10 ± 0.13 × 104 1.67 ± 0.58 × 102 
Frankincense 1.35 ± 0.22 × 105 8.17 ± 1.53 × 105 1.48 ± 0.29 × 106 1.83 ± 0.76 × 102 
Ho wood 5.00 ± 0.50 × 106 7.50 ± 2.65 × 105 1.37 ± 0.28 × 105 4.17 ± 1.44 × 102 
Lemon 3.17 ± 1.15 × 104 1.03 ± 0.28 × 105 8.67 ± 0.76 × 104 4.33 ± 2.31 × 103 
Marjoram 
(Sweet) 2.17 ± 1.53 × 10
5 2.13 ± 0.28 × 106 2.22 ± 0.25 × 106 7.50 ± 1.32 × 103 
Cajeput 2.50 ± 0.87 × 106 9.43 ± 0.40 × 106 3.20 ± 0.26 × 106 1.62 ± 0.25 × 105 
Tea tree 8.00 ± 2.18 × 105 9.33 ± 0.29 × 106 3.97 ± 0.45 × 106 3.17 ± 0.76 × 106 
Cedarwood 2.33 ± 2.31 × 105 2.73 ± 0.33 × 106 3.40 ± 0.36 × 106 3.52 ± 0.18 × 106 
Spearmint 4.33 ± 1.26 × 105 9.17 ± 0.29 × 106 3.67 ± 0.58 × 106 3.68 ± 0.38 × 106 
1 A five-day-old stationary phase B. henselae culture was treated with essential oils or control drugs. The 
beginning CFU for the five-day-old stationary phase B. henselae culture was about 1 × 107 CFU/mL. At 
different time points of drug exposure (day 1, day 3, day 5, and day 7), portions of bacteria were removed, 
washed, and plated on Columbia blood agar for CFU counts. 2 The essential oil concentration used in this 
experiment was 0.032% (v/v). Drug concentrations used in this experiment were based on their Cmax and 
were as follows: 2.4 μg/mL DOX, 0.2 μg/mL AZI, 10 μg/mL GEN, 7.8 μg/mL RIF, 60 μg/mL DAP, 2.9 μg/mL 
methylene blue, and 6.3 μg/mL miconazole. 
 
Carvacrol and cinnamaldehyde as active ingredient of essential oils are highly 
potent against stationary phase B. henselae  
Our previous studies have identified two components, carvacrol and 
cinnamaldehyde, as highly potent active ingredients of oregano and cinnamon bark 
essential oils, respectively, which were effective against B. burgdorferi [51,52]. As 
shown above, oregano and cinnamon bark essential oils were also highly active to kill 
B. henselae, so we tested carvacrol and cinnamaldehyde, two major constituents of 
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these two active essential oils, for their antimicrobial activity against B. henselae. 
Carvacrol and cinnamaldehyde were applied at two concentrations, 0.01% (v/v) and 
0.005% (v/v), respectively, for the drug exposure assay against a five-day-old stationary 
phase B. henselae culture. Clinically used antibiotics and the previously identified 
effective FDA-approved drugs against B. henselae were used at their Cmax as controls. 
As shown in Figure 5, 0.01% carvacrol could eradicate B. henselae cells without viable 
cells being recovered after a five-day drug exposure. Additionally, 0.005% carvacrol led 
to 2 log10 CFU/mL reduction after a seven-day exposure. Cinnamaldehyde was 
especially active such that it rapidly killed all stationary phase B. henselae cells with no 
detectable CFU after one-day exposure when used at the concentration of 0.01%, and 





Figure 5. Time-kill curves of carvacrol and cinnamaldehyde treatment against stationary phase B. 
henselae in comparison with control drugs. Carvacrol, cinnamaldehyde or control antibiotics were 
added to a five-day-old stationary phase culture respectively at time point 0, and at different time points of 
drug exposure (day 1, day 3, day 5, and day 7), portions of bacteria were removed and washed and plated 
on Columbia blood agar for CFU counts. The concentrations of carvacrol and cinnamaldehyde used were 
0.01% (v/v) and 0.005% (v/v). Drug concentrations used in this experiment were based on their Cmax and 
were as follows: 2.4 μg/mL DOX, 10 μg/mL GEN, 7.8 μg/mL RIF, 60 μg/mL DAP, 2.9 μg/mL methylene 










Many chronic persistent bacterial infections pose challenges for clinical treatment, 
including the chronic B. henselae infection, which is thought to be mainly due to 
persister bacteria that are not effectively killed by the currently used antibiotics [23]. To 
address this problem, we successfully applied the SYBR Green I/PI viability assay for 
the high-throughput screen of a herbal product collection and an essential oil collection 
for activity against stationary phase B. henselae as a model of persister drug screens. 
We identified some herbal products that had high activity at 1% (v/v) concentration, 
including extracts of Juglans nigra, Cryptolepis sanguinolenta, Polygonum cuspidatum, 
Scutellaria baicalensis, and Scutellaria barbata. Among these top hits, three herbal 
product extracts could eradicate all stationary B. henselae cells without CFU being 
detected within a seven-day drug exposure at a low concentration of 0.25%, including 
Cryptolepis (Cryptolepis sanguinolenta) 30%, 60%, 90% alcohol extracts, black walnut 
(Juglans nigra) 60%, 90% alcohol extracts, and Japanese knotweed (Polygonum 
cuspidatum) extracts. In addition, we identified 32 essential oils at 0.25% (v/v) 
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concentration which had good activity against stationary phase B. henselae. These 
included four essential oils extracted from plants of genus Citrus (tangerine, bergamot, 
lemon and grapefruit), three from Origanum (two oregano essential oils and marjoram), 
three from Cinnamomum (cinnamon bark, cinnamon leaf and ho wood), two from 
Pelargonium (geranium bourbon and geranium essential oil) and two from Melaleuca 
(cajeput and tea tree). Among these 32 top hits, thirteen single essential oils could 
effectively kill all stationary B. henselae cells without CFU recovered within the seven-
day drug exposure even at a low concentration of 0.032% (v/v), where the essential oils 
of oregano, cinnamon bark, and mountain savory (winter) were the most active ones 
that eradicated all bacteria after a one-day exposure. Some essential oils that showed 
activity by primary screens exhibited poor activity in drug exposure assay, partly due to 
the volatility of essential oils during such a long incubation period. Carvacrol and 
cinnamaldehyde, two active ingredients of effective essential oils, oregano and 
cinnamon bark, respectively, were shown to be extremely active against stationary 
phase B. henselae being able to eradicate all bacterial cells within a seven-day drug 
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exposure, even at a very low concentration ≤ 0.01% (v/v). The MIC determination of 
these active hits showed they were not only active against stationary phase B. henselae 
but also effective in inhibiting the growth of log phase B. henselae, especially the 
essential oil of cinnamon bark. 
The observation that oils from different plant species of the same genus all possess 
antimicrobial ability could serve as a guide in future studies to obtain more active hits 
and decode the antimicrobial mechanism. Here, we identified Citrus, Cinnamomum, 
Origanum, Pelargonium, and Melaleuca as potential genera that might include more 
plants the oils of which are active against B. henselae. Citrus plants constitute one of 
the most valuable and important sources of essential oil served in food processing and 
medical use. Citrus limonum essential oil was reported to have antimicrobial activities 
with preservative effect against Listeria monocytogenes inoculated in minced beef meat 
[64], and remarkable miticidal activity in vitro and in vivo applications against sarcoptic 
mange in rabbits [65]. Besides, the essential oil from Citrus limetta Risso peels could 
alleviate skin inflammation, both tested in vitro and in vivo [66], while the essential oil 
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from Citrus aurantium L. var. amara Engl also had an anti-inflammatory effect [67]. 
Citrus leaf extract was reported to reduce blood pressure and vascular damage in 
repeatedly heated palm oil diet-induced hypertensive rats [68]. These studies indicated 
Citrus plants could serve in different health care treatments including antimicrobial 
function. Our study was the first to identify their activity against B. henselae. 
Previous studies have shown that oregano oil has antibacterial activity against three 
Gram-positive and two Gram-negative bacteria of their growing log phase [69]. It was 
also reported to be highly effective against stationary phase B. burgdorferi [51]. 
Cinnamon, clove bud, and allspice were well-known as flavors for food processing, 
while they were both found to have excellent activity against B. burgdorferi stationary 
phase cells in vitro, even better than the persister drug daptomycin [51,52]. Allspice was 
also known to have antibacterial activities on many organisms [70]. Here, for the first 
time, we identified essential oils of oregano, cinnamon, clove bud and allspice as having 
highly potent activities against both the log phase and stationary phase B. henselae. It 
is interesting to note that the high activity of these common essential oils against both 
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Borrelia and Bartonella, such as oregano, cinnamon bark, and clove bud, indicated that 
they had the potential to be active against both Borrelia and Bartonella persistent 
infections, which clinically may be present as coinfections [16]. However, it is also worth 
noting that some other essential oils including frankincense, ylang-ylang, fir needle, 
mountain savory (winter), elemi, and vetiver, are preferentially more active against B. 
henselae. This suggests preferential activity of some essential oils against different 
bacterial species that possess different cell surface structures, efflux, and physiology. 
Other essential oils identified as effective in our study have also been proved to 
have good biological activities by previous studies. It was reported that frankincense 
and geranium essential oils could suppress tumor progression through the regulation of 
the AMPK/mTOR pathway in breast cancer [71]. Geranium essential oil could eradicate 
enterococcal biofilm at a concentration of 150 mg/mL without bacteria developing 
resistance to it; thus it could be a possible alternative to other antimicrobials during 
endodontic procedures [72]. Frankincense was reported to have anti-inflammatory and 
antibacterial effects [73]. Mountain savory has been proved to be highly active against 
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methicillin-resistant Staphylococcus aureus (MRSA), Salmonella typhimurium and L. 
monocytogenes [74-76]. According to previous studies, fir honeydew honey had strong 
antimicrobial activity against S. aureus, A. baumannii, P. aeruginosa, E. coli and many 
kinds of fungi [77-79]. Ylang-ylang products have a wide variety of bioactivities including 
antimicrobial, antibiofilm, anti-inflammatory, anti-vector, insect-repellent and so on, 
demonstrating it to be a useful plant to agriculture and medicine [80]. Citronella was 
reported to have antifungal and antibiofilm activity as well as antimicrobial activity 
against Staphylococcus [81,82]. Extracts from Canarium were proved to be active 
against MRSA and P. aeruginosa [83]. Essential oils of vetiver were active against S. 
aureus and showed good antifungal and cytotoxic activities [84,85]. Here, for the first 
time, we identified the remarkable activity of these essential oils active against both log 
phase and stationary phase B. henselae. 
Similarly, plant species of which the herbal extracts we found to be active against B. 
henselae have also been reported to have various biological activities by previous 
studies. Different parts of various species from genus Juglans have shown pain-
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relieving, antioxidant, antibacterial, antifungal and antitumor activities [86-88]. In 
particular, different Juglans regia cultivars and one active ingredient, juglone, showed 
excellent antifungal activity and Juglans nigra exhibited both bacteriostatic activity and 
bactericidal activity against Borrelia based on in vitro studies [58,89]. Previous studies 
have profiled the phytochemicals of Juglans plants, including different types of steroids, 
flavonoid C-glycoside, flavones, essential oil component, tannins and miscellaneous 
[90]. Many active ingredients of Juglans with potential importance to human health were 
identified, such as juglone, phenolic acids, flavonoids and catechins, and the safety as 
well as efficacy of these compounds were systematically assessed, concluded to be 
with great benefit [91-95]. A study comparing leaf essential oils of J. regia and J. nigra 
further showed J. nigra leaf oil was less phytotoxic [96]. Cryptolepis sanguinolenta and 
its constituents were reported to have many excellent biological activities including 
antibacterial, antifungal, anti-inflammatory, anticancer, antimalaria and anti-amoebic 
properties [59,97-101]. A systematic review has assessed the phytochemistry and 
pharmacology of Cryptolepis sanguinolenta and concluded that although there have 
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been data pointing to the toxic potential of this plant, it is still a promising source of 
potential agent(s) that can aid in many disease therapies [102]. Among constituents and 
secondary metabolites of the plant identified with antimicrobial activity, an alkaloid 
called cryptolepine was the most well-studied and considered to be the most important 
active component. Cryptolepine was reported to have a lytic effect on S. aureus as seen 
in SEM photomicrographs which led to altered cell morphology and could intercalate 
into DNA at cytosine-cytosine sites or inhibited the activity of topoisomerase causing 
DNA damage [103-105]. Future studies are needed to decode more specific 
antibacterial mechanisms of cryptolepine as well as other active ingredients when used 
against bacterial pathogens including B. henselae. Polygonum cuspidatum has been 
documented to have antibacterial effects against Vibrio vulnificus [106], Streptococcus 
mutans [107] and streptococcus associated biofilms [108]. Its constituents have also 
been shown to have antimicrobial, anti-tumor, anti-inflammatory, neuroprotective, and 
cardioprotective effects [109-113]. One of the most active constituents is a polyphenol 
called resveratrol, which was reported to be active against log phase Borrelia 
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burgdorferi and Borrelia garinii by in vitro testing [58]. In addition, another active 
constituent called emodin (6-methyl-1,3,8-trihydroxyanthraquinone) has been shown to 
have activity against stationary phase Borrelia burgdorferi cells [114]. There is a study 
unraveling the action mechanism of Polygonum cuspidatum using a network 
pharmacology approach, which suggested that polydatin might be the critical active 
component of Polygonum cuspidatum [115]. Polygonum cuspidatum has been found to 
have minimal toxicity in animal and human studies. It is reported that gastrointestinal 
upset and diarrhea can occur as a side effect but can resolve with lowering of doses or 
cessation of therapy [116]. Our study is the first to identify the antimicrobial activity of 
extracts from Juglans nigra, Cryptolepis sanguinolenta, and Polygonum cuspidatum 
against stationary phase B. henselae. In addition, considering the possibility of 
coinfection caused by Borrelia burgdorferi and B. henselae during Lyme disease 
development, the overlap of active herbal products against both B. henselae identified 
in our study and against B. burgdorferi according to previous studies, including Juglans 
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nigra, Cryptolepis sanguinolenta, and Polygonum cuspidatum, should provide a 
promising strategy for better treatment of coinfections with both pathogens [53]. 
According to our data in Table 1, Table 3, Table 5, and Figure 1-5, some clinically 
used antibiotics for treating Bartonella-associated infections including AZI and DOX 
showed weak activity in eradicating stationary phase B. henselae cells, which coincides 
with the reported discrepant antibiotic efficacies between in vitro MIC data and clinical 
data from patients [30]. The poor activities of current clinically used antibiotics against 
stationary phase B. henselae as shown in our study could partly explain the treatment 
failure due to persistent infection. This discrepancy may be partly due to the 
antibacterial mechanisms of these antibiotics. DOX inhibits bacterial protein synthesis 
by binding to their 30S ribosomal subunit [117]. AZI could also inhibit bacterial protein 
synthesis by binding to the 50S ribosomal subunit, and thus prevent bacteria from 
growing [118]. Although these antibiotics all target growing bacteria, they are not very 
effective at killing non-growing stationary phase B. henselae, and thus could lead to the 
treatment failure against persistent and chronic infections. However, the herbal extracts 
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and essential oils should be promising candidates to treat persistent B. henselae 
because of their abundant content of active organics including steroids, flavones, 
tannins and so on. These organics are lipophilic and could target the bacterial cell 
membrane, which is an important target of persister drugs like pyrazinamide [119] and 
daptomycin [120], especially when persistent bacterial cells aggregated together (Figure 
1 and Figure 3) and protected cells located towards the center of the aggregates from 
attack by antimicrobial agents. However, it should also be noted that the high 
lipophilicity of essential oils might cause B. henselae cells or biofilm structures to be 
dissolved, leading to a reduction of the dead cell number and as a result, the residual 
viability percentage by the SYBR Green I/PI assay might be misinterpreted. 
Furthermore, some nonpolar essential oils are DMSO-insoluble, which could just form 
emulsions. They are hard to be distributed evenly in the bacterial culture, leading to 
different concentrations in different local areas and non-uniform antibacterial effects. It 
is also worth noting that as DMSO could permeabilize the bacterial membranes, it could 
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increase the antibacterial effect of the herbal products and essential oils by increasing 
the bacterial susceptibility to lipophilic compounds. 
Despite the promising findings of the herbal extracts and essential oils active 
against B. henselae, future studies are needed to identify the active ingredients of these 
herbs and to decode their specific antimicrobial mechanisms. Here we just tested two 
active ingredients, carvacrol, and cinnamaldehyde, which showed excellent ability to 
eradicate stationary phase B. henselae even at a much lower concentration (≤ 0.01%) 
than would have been expected from the studies with the related essential oil samples. 
It is still worth noticing that according to the concentration of the original stock, 0.005% 
carvacrol or cinnamaldehyde was approximately equal to 50 μg/mL, which was a 
concentration similar to the Cmax of some clinically used antibiotics, such as DAP. 
Thus, on a weight basis, the antimicrobial activity of carvacrol and cinnamaldehyde 
against stationary phase B. henselae was comparable to that of effective FDA-approved 
antibiotics, including GEN, RIF, DAP, and methylene blue, which could eradicate all B. 
henselae cells within the seven-day drug exposure when used at their Cmax. Although 
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if compared on a molar basis, as the molecular weight of carvacrol and cinnamaldehyde 
are lower than that of most antibiotics mentioned above, these ingredients are not as 
effective as currently used antibiotics. Therefore, it would be of interest to test 
compounds like juglone, cryptolepine, and resveratrol, which are known active 
components of black walnut, cryptolepis, and Japanese knotweed herbs on B. henselae 
in future studies. Some previous studies have identified the main ingredients of some 
active essential oils such as mountain savory, thyme, lemongrass, limette, and cumin, 
including geranial, β-pinene, thymol, γ-terpinene, citronellal and so on [121]. Also, 
different parts of the plant might have different antimicrobial activities because of 
varying concentrations of the active compounds they contained, and different solvents 
used to extract the compounds could also significantly affect their activity. Therefore, 
the antimicrobial activity and pharmacokinetic profiles of active components should be 
studied thoroughly in the future, as well as the optimal extraction strategy to obtain 
maximum effective ingredients using minimum amount of plant materials, in order to 
better determine the utility and practicality of these active herbs. For example, based on 
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GC-MS profiles of active herbal products or essential oils, we should obtain a list of 
potential active ingredients. Future studies are needed to identify the activity of these 
ingredients on growing B. henselae or persistent B. henselae models compared with 
currently used antibiotics, both in vitro and in vivo. Pharmacokinetic studies are needed 
to measure the Cmax and half-life, as well as the potential toxicity of these active 
ingredients to determine whether they could obtain the expected concentration in the 
human body, while being free of toxic side effects. 
Another promising strategy for developing a more effective treatment for Bartonella 
infections is the drug combination of active ingredients of herbal products or essential 
oils with antibiotics to avoid resistance development and improve the efficacy of the 
treatment. Future studies are needed to evaluate drug combinations of two or more 
newly identified active herbal ingredients with current clinically used drugs, in order to 
better target diverse bacterial populations of different phases or forms that can happen 
in the host as indicated by the Yin-Yang model [23]. There were some previous studies 
of evaluating the antimicrobial activity of combined essential oil samples against 
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multidrug resistance (MDR) E. coli, K. pneumoniae, MRSA, S. epidermidis, 
Propionibacterium acnes, as well as airborne bacteria and fungi in hospital rooms, and 
some of the essential oil combinations did have better activity than when used alone 
[122–124]. 
Regarding the phenomenon of bacterial persistence, many pathogenic bacteria are 
able to predominantly colonize body surfaces and tissues in multicellular aggregates 
such as biofilms [125, 126]. Formation of these sessile communities, which limits the 
access of the immune system components and drugs, combined with the persisters’ 
inherent resistance to antimicrobial agents, is at the root of many persistent and chronic 
bacterial infections or frequent relapse after treatment. As biofilms were suggested to 
play an important role in chronic B. henselae infections, future studies are required to 
test active drug candidates and drug combinations on B. henselae biofilm models to 
further address the problem of bacterial persistence. 
In this study, we identified a range of herbal products and essential oils with high 
activity against stationary phase B. henselae in vitro. Because B. henselae can reside 
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and propagate inside erythrocytes and/or endothelial cells in humans and animals 
[13,127], which could provide a shelter that protects them from the host immune 
responses and exposure to antibiotics, future studies are needed to evaluate the 
activities of selected herbal products and essential oils against intracellular B. henselae. 
The active ingredients of many effective herbal products and essential oils remain 
unknown, and it will take substantial effort to characterize and identify the active 
components, which is beyond the scope of the current study. These should be studied 
thoroughly in the future in order to identify the active components, decode the 
antimicrobial mechanism, and further evaluate their activity in vivo. We are fully aware 
that while the number of active components of herbal products and essential oils may 
be subject to variations from different batches or sources, just like any natural products, 
this should not change the overall findings or conclusions of the study. As far as we 
know, the effective concentration on a weight basis of two highly active ingredients, 
carvacrol, and cinnamaldehyde, was comparable to the Cmax of some antibiotics, 
indicating they could serve as promising drug candidates that may achieve efficacy 
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when used in vivo, which requires further pharmacokinetic studies. Many previous 
studies have demonstrated the activity of essential oils in vivo. For example, Citrus 
limon essential oil was proved to have high miticidal activity in rabbit models [65]. The 
safety and activity of the essential oil from Citrus limetta Risso peels for alleviating skin 
inflammation was identified using both rabbit and mouse models [66], and frankincense 
essential oil was shown to modulate tumor growth in a xenograft mouse model [71]. 
Further validation using appropriate animal models of Bartonella infections is required to 
assess the safety and efficacy of identified active herbal medicines and essential oils or 
their active components in vivo. Our study was performed with B. henselae and future 
studies are needed to test if the findings here apply to other B. henselae strains and 
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Table S1. Herbal product sources, validation, and extract details 
Herbal 
Product 
Plant or Ingredients 
of Herbal Products Source Validation/ID Extract Details 
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30, 60, 90% 
ETOH by 
Heron Botanicals 









Samento Uncaria tomentosa bark 
NutraMedix, LLC 




















































Hu zhang Polygonum cuspidatum 
Hawaii Pharm LLC 
(Wildcrafted)  
















30, 60, 90% 
ETOH by 
Heron Botanicals 







30, 60, 90% 
ETOH by 
Heron Botanicals 
Ban zhi lian Scutellaria barbata 






by Hawaii Pharm 
LLC (Honolulu, 
HI) 
Cumanda Campsiandra angustifolia bark 
NutraMedix, LLC 




Gou Teng Uncaria rhynchophylla Hawaii Pharm LLC   





jiang Dipsacus fullonum 













with D. asper 
sample prior to 
testing) 





























cineole, α-terpineol, bornyl acetate, 
etc. 
[1] 
Oregano Origanum vulgare hirtum herbs 
thymol, γ-terpinene, carvacrol, p-
cymene, myrcene, etc. [2] 
Elemi Canarium luzonicum resin 
elemol, elemecin, sabinene, α-






Satureja montana herbs carvacrol, borneol, carvacrylacetate, α-terpineol, thymol, etc. [4] 
Cedarwood Cedrus deodora wood wikstromol, matairesinol, benzylbutyrolactol, BDFD [5] 
Ylang ylang Cananga odorata flowers 
linalool, β-caryophyllene, α-
humulene, γ-muurolene, germacrene 
D, (3E,6E)-α-farnesene, δ-cadinene, 
benzyl benzoate 
[6] 
Citronella Cymbopogon winterianus leaves 
citronellal, isomenthone, citronellol, 
geraniol, limonene, etc. [7] 
Clove bud 1 Eugenia caryophyllata bud 
eugenol, eugenyl acetate, β-
caryophyllene, carvacrol, 
cinnamaldehyde, thymol, etc. 
[8] 
Clove bud 2 Syzygium aromaticum L bud 
eugenol, β-caryophyllene, eugenyl 








linalool, citronellol, iso-menthone, 
geraniol, citronellyl formate, geraniol 
formate, etc. 
[10] 
Allspice Pimenta officinalis berries 
eugenol, methyleugenol, β-
caryophyllene, α-humulene, etc. [11] 
Vetiver Vetiveria zizanoides root 
cycloisolongifolene, khusimene, β-







eugenol, benzyl benzoate, linalool, 
cinnamaldehyde, etc. [13] 
Geranium Pelargonium asperum herbs 
citronellol, citronellyl ester, geraniol, 
buthyl anthranilate, etc. [14] 
Bergamot Citrus bergamia fruit peel limonene, β-pinene, γ-terpinene, linalool, linalyl acetate, etc. [15] 


















cymene, β-phellandrene, etc. 
[17] 
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Fir needle Abies siberica needles α-pinene, camphene, β-pinene, Δ3-carene, limonene, bornyl acetate, etc. [18] 
Grapefruit Citrus paradisi peel limonene, β-myrcene, α-pinene, etc. [19] 
Spearmint Mentha spicata flowering herbs 
carvone, limonene, 1,8-cineole, β-
caryophyllene, germacrene D, etc. [20] 
Tangerine Citrus reticulata fruit peel citronellal, thymol, geranyl acetate, β-elemen, germacrene B, etc. [21] 
Tea tree Melaleuca alternifolia leaves 
α-pinene, α-terpinene, 1,8-cineole, γ-
terpinene, terpinolene, terpinen-4-ol, 
α-terpineol, etc. 
[22] 
Lemon Citrus limonum peel 
β-pinene, limonene, linalool, α-
terpineol, linalyl acetate, nerolidol, 
farnesol, etc. 
[23] 
Ho wood Cinnamomum camphora 
twigs 
and bark 
D-camphor, 1,8-cineole, α-terpineol, 
while D-camphor, linalool, 1,8-
cineole, etc. 
[24] 
Frankincense Boswellia serrata resin 
α-pinene, α-thujene, methylchavicol, 
sabinene, methyleugenol, myrcene, 
limonene, p-cymene, etc. 
[25] 
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